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Abstract: Neuropathological changes associated with Alzheimer’s disease 
(AD) precede symptom onset by more than a decade. Possession of an 
Apolipoprotein-E (APOE) ε4 allele is the strongest genetic risk factor for late 
onset AD. Cross-sectional studies of cognitively intact elders have noted 
smaller hippocampal/medial temporal volumes in ε4 carriers (ε4+) compared 
to ε4 non-carriers (ε4-). Few studies, however, have examined long-term, 
longitudinal, anatomical brain changes comparing healthy ε4+ and ε4- 
individuals. The current five-year study examined global and regional volumes 
of cortical and subcortical grey and white matter and ventricular size in 42 
ε4+ and 30 ε4- individuals. Cognitively intact participants, ages 65-85 at 
study entry, underwent repeat anatomical MRI scans on three occasions: 
baseline, 1.5, and 4.75 years. Results indicated no between group volumetric 
differences at baseline. Over the follow-up interval, the ε4+ group 
experienced a greater rate of volume loss in total grey matter, bilateral 
hippocampi, right hippocampal subfields, bilateral lingual gyri, 
parahippocampal gyrus, and right lateral orbitofrontal cortex compared to the 
ε4- group. Greater loss in grey matter volumes in ε4+ participants were 
accompanied by greater increases in lateral, third and fourth ventricular 
volumes. Rate of change in white matter volumes did not differentiate the 
groups. The current results indicate that longitudinal measurements of brain 
atrophy can serve as a sensitive biomarker for identifying neuropathological 
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changes in persons at genetic risk for AD and potentially, for assessing the 
efficacy of treatments designed to slow or prevent disease progression during 
the preclinical stage of AD. 
 
Keywords: Longitudinal Studies, MRI Scans, Alzheimer Disease, ApoE4 
 
Introduction 
 
The neuropathological changes associated with Alzheimer’s 
disease (AD) may occur decades prior to the onset of clinical 
symptoms.1 Identification of individuals in the preclinical stage of AD is 
essential to developing successful interventions designed to prevent or 
slow down the neuropathological processes leading to cognitive decline 
and dementia. In addition to advancing age and a family history of 
dementia,2 the ε4 allele of the Apolipoprotein-E (APOE) gene is a well-
recognized AD risk factor.3 Possession of the ε4 allele is associated 
with a greater rate of hippocampal and medial temporal lobe atrophy 
in patients diagnosed with Mild Cognitive Impairment (MCI) and AD.4,5 
Conceivably, a greater rate of hippocampal and medial temporal lobe 
atrophy could also be used to identify persons during the preclinical 
stage of AD. One approach would involve the longitudinal study of 
brain atrophy comparing cognitively intact elders possessing one or 
both ε4 alleles with similarly aged non-carriers. 
 
Longitudinal studies of brain atrophy comparing ε4 carriers and 
non-carriers show mixed results (see Table 1). Most of these studies 
focus on the hippocampus, due to its known relationship with early AD 
pathogenesis.6 Some longitudinal studies have demonstrated that 
cognitively intact elders possessing the ε4 allele experience greater 
hippocampal atrophy over time compared to non-carriers,7-9 although 
these results have not been demonstrated in other studies.10-12 
Notably, most of these studies measured the rate of atrophy based on 
two MRI assessments.  
 
Only a few studies in Table 1 examined longitudinal changes in 
brain regions outside the medial temporal lobes. A measure of total 
brain volume demonstrated a greater rate of atrophy in ε4 carriers 
than non-carriers.8 In one study, total grey matter volume atrophied 
at a faster rate in ε4 homozygotes relative to ε4 heterozygotes and 
non-carriers.13 Healthy ε4 carriers also experienced a greater rate of 
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volume loss in the temporal lobes compared to non-carriers.14 No 
study has yet reported comprehensive rates of change in global and 
regional volumes comprising the entire brain. 
 
The current study, therefore, evaluated the influence of the ε4 
allele on brain volume changes in cognitively intact elders who 
underwent repeat cognitive testing and anatomical MRI at study entry 
and after 1.5 and 4.75 years. The three scan sessions enable a more 
precise examination of the slope of volume change over time. The MRI 
volumetric analysis, based on Freesurfer software, enabled a 
comprehensive examination of global and regional grey and white 
matter volumes and ventricular size, as well as specific examination of 
the hippocampus and hippocampal subfields. We employed a 
longitudinal linear mixed-effects (LME) analysis that permitted 
modeling of the precise time intervals between assessments as well as 
allowance for missing observations. We predicted that ε4 carriers 
would exhibit greater atrophy than non-carriers in the hippocampus 
and other cortical regions that are particularly vulnerable to AD 
pathogenesis, such as the medial temporal4 and frontal regions.15 
 
Materials and Methods 
 
Participants 
 
The recruitment strategy for this study, described in detail in 
Seidenberg, et al.,16 involved over-sampling persons at genetic risk for 
AD based on the presence of an APOE ε4 allele. Briefly, healthy older 
adults between the ages of 65 and 85 were recruited from newspaper 
advertisements. Screening via telephone of 459 individuals was 
conducted for willingness to participate and to exclude participants 
based on: MRI scanning criteria (e.g., weight inappropriate for height, 
ferrous objects within the body, history of claustrophobia); non-right 
handedness; depression [Geriatric Depression Scale (GDS)17 score > 
20]; impaired activities of daily living [Lawton Instrumental Activities 
of Daily Living (IADL)18 scale < 5]; current use of psychoactive 
medications; and history of major neurological, medical, or psychiatric 
(DSM-IV Axis-I criteria) diseases or disorders. All procedures were 
approved by the Institutional Review Board of the Medical College of 
Wisconsin, which had oversight of this study. Written informed consent 
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was obtained from all participants and they received financial 
compensation for their participation. 
 
Of those meeting eligibility criteria, 109 agreed to undergo APOE 
genotype testing from blood samples, a neuropsychological evaluation, 
and an MRI scanning session. APOE genotype was determined using a 
polymerase chain reaction method. DNA was isolated with Gentra 
Systems Autopure LS for Large Sample Nucleic Acid Purification.19 We 
excluded 31 ε4- participants who had a family history (FH) of AD to 
isolate APOE as the primary AD genetic risk factor. FH was defined as 
a reported first degree relative with a history of gradual decline in 
memory and other cognitive domains, and confusion. Of the remaining 
78 participants, only those with a minimum of two technically 
adequate MRI scans were included in the final sample. Six participants 
were excluded because they had only baseline data: withdrawal from 
study (3), scan failure/refusal (2), and lost to followup (1). 
 
The final sample consisted of 72 participants divided into two 
groups: 1) the APOE ε4 positive group (ε4+; n=42), who were carriers 
of one or both ε4 alleles (ε2/ε4: 1; ε3/ε4: 39; ε4/ε4: 2); and 2) the ε4 
negative group (ε4-; n=30), (ε2/ε3: 2; ε3/ε3: 28). Table 2 shows the 
baseline characteristics of the ε4+ and ε4- groups. No significant 
group differences were observed for age or sex. A non-significant 
trend was observed for education, with a mean 1.3 years of greater 
attainment observed in the ε4+ than ε4- group; as a result, all 
subsequent analyses employed education as a covariate. Two-thirds of 
the ε4+ group had a FH of AD, whereas none of the ε4- group had a 
FH. None of the participants had clinical levels of depression (GDS) or 
problems with activities of daily living. 
 
Mean follow-up intervals for the ε4+ participants were 1.5 years 
(SD = 0.1) and 4.7 years (SD = 0.4). For the ε4- participants, the 
follow-up intervals were 1.5 years (SD = 0.2) and 5.0 years (SD = 
0.5). No significant group differences were observed. Three 
participants (all ε4+) had baseline and second follow-up scans, but no 
first follow-up scan; 21 participants (12 ε4+; 9 ε4-) completed 
baseline and first follow-up scans, but were unable to be scanned at 
the second follow-up due to: health decline (6), deceased (5), lost 
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to follow-up (3), refused scan (3), moved away (3), and no longer safe 
to be scanned (1). No group differences were observed in attrition 
rates at each of the two follow-up scan sessions. 
 
Procedure 
 
For each session, neuropsychological testing and MRI were 
conducted on the same day. Participants were asked to refrain from 
alcohol use for 24 h and caffeine use 12 h prior to testing. The 
neuropsychological test battery consisted of the Mini Mental State 
Examination (MMSE) [20], Mattis Dementia Rating Scale 2 (DRS-2),21 
and Rey Auditory Verbal Learning Test (RAVLT).22 
 
MRI Acquisition and Processing 
 
High-resolution, three-dimensional spoiled gradient-recalled at 
steady-state (SPGR) anatomic images were acquired on a General 
Electric (Waukesha, WI) Signa Excite 3.0 Tesla short bore scanner 
equipped with a quad split quadrature transmit/receive head coil (TE = 
3.9 ms; TR = 9.5 ms; inversion recovery (IR) preparation time = 450 
ms; flip angle = 12°; number of excitations (NEX) = 2; slice thickness 
= 1.0 mm; FOV = 24 cm; resolution = 256 × 224). A scanner upgrade 
took place near the end of the final retest period. Six ε4+ participants 
and one ε4- had their third scan conducted on a GE MR750 3.0 Tesla 
scanner (TE = 3.9 ms; TR = 9.6 ms; inversion recovery (IR) 
preparation time = 450 ms; flip angle = 12°; number of excitations 
(NEX)=1; slice thickness = 1.0 mm; FOV = 24 cm; 
resolution=256×224). A between-scanner comparison showed no 
systematic differences. Whole brain and regional volumes were derived 
from T1- weighted SPGR images using the longitudinal stream in 
Freesurfer v.5.1 software.23 
 
Statistical analysis 
 
All data were analyzed using R software, version 3.2.2. A 
longitudinal LME analysis was used to model the effects of genetic risk 
and time on anatomical volumes, with baseline age, education and 
intracranial volume included as covariates. LME permits an unequal 
number of within-subject observations, making this technique flexible 
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in cases where missing data may occur. The level-one random effects 
model was linear within-subject volume as a function of time at 
baseline and was used to assess volume differences at baseline 
between carrier groups. Time was flexibly expressed as fractional 
number of years since baseline for each observation in each subject.  
 
The level-two fixed effects model estimated group differences in 
the slope of volume change with years post baseline as the measure of 
time. The non-carrier (ε4-) group provided the base (i.e., reference) 
model; differences in rate of atrophy of the carrier (ε4+) group were 
modeled with respect to the ε4- group. Thus, a statistically significant 
slope in the non-carrier group is reflected by a rate of change greater 
than 0 (data column 3 in Tables 3-7). A statistically significant group 
difference (carrier vs. non-carrier) in slope is shown in data column 4 
of Tables 3-7. A statistically significant slope in the non-carrier group 
(data column 3), but a non-significant slope difference between the 
carrier and non-carrier groups (data column 4), indicates that the rate 
of change in both groups is comparable (i.e., normal aging effect).  
 
The level-two model included nuisance variables as covariates, 
including baseline age, intracranial volume and education. Residuals 
were visually inspected using quantile–quantile plots to confirm the 
assumption of normality. Coefficients, standard errors, t-statistics 
and associated p-values were tabulated for each region. False 
discovery rate was applied to correct for multiple comparisons; this 
correction was applied separately to different classes of data (e.g., 
white matter vs. grey matter volumes). Statistically significant 
negative slopes in the ε4- group represent atrophy as a function of 
time that is comparable in both carriers and non-carriers. Statistically 
significant negative slopes in the ε4+ vs. ε4- groups represent greater 
rates of atrophy in ε4 carriers. Thus, regions that show greater rates 
of atrophy in ε4 carriers compared to non-carriers represent atrophy 
specific to the ε4 allele. 
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Results 
 
Baseline Cognitive Functioning 
 
No significant group differences were observed on the MMSE, 
the total score and subscales of the DRS-2, or the RAVLT; these 
measures were well within the normal ranges.  
 
LME Analyses 
 
A quadratic model was also considered, but comparison of the 
Akaike Information Criterion (AIC) for each model indicated that the 
linear model was preferred. Table 3 summarizes results of the LME 
analyses applied to the total left and right hippocampal volumes and 
parcellated hippocampal subfields. No significant group differences 
were observed at baseline (intercept) between the ε4- and ε4+ 
groups. No differences over time (slope) were observed in the ε4- 
group. In contrast, the ε4+ group showed significantly greater rates of 
change than the ε4- group in the left and right hippocampi (see top 
panel of Figure 1) and multiple right sided hippocampal subfields: 
Cornu Ammonis (CA)2/3, CA4/DG, presubiculum, and subiculum 
(changes in CA2/3 and CA4/DG are shown in the middle panel of 
Figure 1). 
 
Table 4 summarizes results of whole brain cortical grey matter 
(GM), white matter (WM), and ventricular volumes. No baseline group 
differences were observed. Over time, both groups showed 
significantly decreased volume in the right and left cortical WM and 
increased volume within the right and left lateral, inferior lateral, third, 
and fourth ventricles. The ε4+ group showed statistically greater rates 
of atrophy in bilateral cortical GM and greater increases in volume of 
the lateral, inferior lateral, and third ventricles compared to the ε4- 
group. Longitudinal changes in the left and right lateral ventricles are 
shown in the bottom panel of Figure 1. 
 
Tables 5 and 6 summarize right and left cortical GM volumes, 
respectively. No baseline group differences were observed. Decreased 
volume of the right transverse temporal cortex and the left middle 
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temporal, pars orbitalis, and superior temporal gyrus were observed in 
the ε4- group over time. The ε4- group also showed increased volume 
in left lingual gyrus over time. Compared to the ε4- group, the ε4+ 
group had a greater rate of atrophy within the lingual and 
parahippocampal gyri (PHG) and right lateral orbitofrontal cortex 
(OFC). 
 
Tables 7 and 8 summarize right and left cortical WM volumes, 
respectively. No significant group differences were observed at 
baseline. The ε4- group experienced reduced volumes over time in 19 
bilateral WM regions, six unique regions within the right hemisphere, 
and 1 within the left hemisphere. Notably, the rate of decline in WM 
regions did not differ between the ε4+ and ε4- groups. 
 
Table 9 summarizes results of subcortical volumetric analyses. 
No significant between group differences were observed at baseline. 
Over time, the ε4- group had reduced volumes in the right and left 
putamen, left accumbens, and left amygdala. No differences were 
observed in the rate of change in volume over time between the ε4+ 
and ε4- groups. 
 
Discussion 
 
Our cognitively intact and healthy ε4 carriers and non-carriers, 
who were enrolled between the ages of 65 and 85, did not 
demonstrate any brain volumetric differences at study entry. Over the 
course of the five-year follow-up interval, the rate of brain atrophy 
was significantly greater in the carriers than in the non-carriers. 
Consistent with prior investigations (see Table 1), we observed greater 
shrinkage of the hippocampi in carriers than non-carriers. When 
examining hippocampal subfields, we observed shrinkage primarily of 
the CA2,3, CA4-DG, presubiculum and subiculum regions in the right 
hemisphere. The greater atrophy seen in carriers relative to non-
carriers is not confined to the hippocampus, but extends to the lingual 
and parahippocampal regions, as well as the lateral orbitofrontal 
cortex. Carriers also experienced global atrophic changes over time, 
with greater reductions in total cortical GM and increases in the lateral 
and third ventricles, compared to non-carriers. Finally, while 
longitudinal reductions in total and regional WM volumes were 
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prominent as part of the aging process, no differences in the rate of 
WM atrophy were observed between carriers and non-carriers. 
 
These findings suggest that possession of the APOE ε4 allele is 
associated with more accelerated brain atrophy rates in healthy elders, 
suggesting that some of the carriers may be experiencing the effects 
of underlying AD-related neuropathology. Although we do not have 
independent confirmation that the greater rates of atrophy in our 
carriers are linked to AD neuropathology (i.e., evidence of amyloid-β 
or tau from CSF or PET scans), we9 have previously reported that a 
significantly higher percentage of our carrier group converted to a 
diagnosis of MCI at the five year follow-up examination compared to 
our non-carrier group. In the current sample, which overlaps but is not 
identical to our previously published study,9 12 of 72 participants 
(16.7%) met MCI criteria within the 5- year study period. Of these 
participants, 10 were carriers and two were non-carriers. Thus, 10 of 
42 (23.8%) carriers, but only 2 of 30 (6.7%) non-carriers, converted 
to MCI. Given this association and the relatively small overall number 
of MCI converters, it is not possible to examine the separate influence 
of MCI conversion and carrier status on regional brain atrophy rates. 
 
The precise mechanisms that link AD pathogenesis with the 
APOE ε4 allele are not well understood. The APOE gene is related to 
cholesterol metabolism and axonal repair after injury. The APOE ε4 
allele negatively influences synaptic functioning and dendritic 
branching.24 Other studies have suggested that ε4 confers a greater 
risk to developing AD through inhibiting amyloid-β (Aβ) clearance.25,26 
Aβ detected in healthy elders has been associated with neural 
degeneration27 and specifically with hippocampal atrophy.28 The 
current working hypothesis suggests that abnormal processing of Aβ 
peptides and associated formation of Aβ plaques precede 
neurodegenerative changes (i.e., atrophy) and cognitive dysfunction.1 
 
Our results confirm previous research indicating that the most 
profound and earliest AD-related atrophic changes are observed within 
the hippocampal region. Hippocampal volume loss tracks AD disease 
progression, with MCI patients showing greater hippocampal atrophy 
compared to healthy elders and AD patients showing more pronounced 
hippocampal atrophy than MCI patients.29 Our study extended 
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previous investigations by examining volumetric rates of change in 
hippocampal subfields. Our carriers demonstrated greater rates of 
atrophy in CA2/3, CA4/dentate gyrus, presubiculum, and subiculum 
layers (right hemisphere), whereas the CA1, fimbria, and hippocampal 
fissure were not affected. Interestingly, although both the right and 
left total hippocampal volumes showed greater rates of atrophy in 
carriers compared to noncarriers, and both right and left hippocampal 
subfields showed greater atrophy in the carriers than non-carriers, 
only group differences in the right hippocampal subfields survived FDR 
correction. This outcome may reflect statistical factors, such as sample 
size and measurement variability, rather than true asymmetric rates of 
atrophy within the subfields. Cross-sectional studies have 
demonstrated smaller CA3 and dentate gyri30 and subiculum4 in 
healthy elders with the ε4 allele. Furthermore, CA1 and subicular 
atrophy has been shown to predict conversion from normal aging to 
amnestic MCI over 6 years in a study that did not consider APOE 
genotype.31 
 
Our study found a greater rate of ventricular dilatation in 
carriers relative to noncarriers. This increased rate of enlargement 
occurred primarily within the lateral and third ventricles, with the 
fourth ventricle being spared. Although we did not observe baseline 
differences in ventricular volumes between carriers and non-carriers, a 
cross sectional study reported greater ventricular volumes in healthy 
older ε4 carriers relative to age matched non-carriers.32 Greater 
longitudinal rates of change in lateral ventricular size are common in 
AD, with rates of change in MCI and AD patients significantly greater 
than in healthy elders.33 CSF measures of Aβ have been associated 
with greater ventricular enlargement over time in healthy elders, 
especially in ε4 carriers.34 
 
Only one prior study13 has examined total GM atrophy in a 3.6-
year longitudinal study of elderly ε4 carriers. They observed a greater 
total cortical GM atrophy rate in ε4 homozygotes than in ε4 
heterozygotes and non-carriers using voxel based morphology (VBM). 
In contrast to our study in which 95% of the carriers were 
heterozygotes, no differences in GM atrophy rates were observed 
between heterozygotes and non-carriers. These conflicting findings 
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may be related to possible methodological differences between VBM 
and Freesurfer in calculating bran volumes. 
 
Carriers exhibited greater atrophy in bilateral lingual and 
parahippocampal gyri and in right lateral orbitofrontal cortex. The 
lingual and parahippocampal gyri appear to be particularly vulnerable 
to AD-related neuropathology. Specifically, reduced cerebral metabolic 
rates have been reported in these regions for ε4 carriers vs. non-
carriers,35 and atrophy in these regions predicts conversion from MCI 
to AD.36 Similarly, orbitofrontal cortex volume has been shown to 
distinguish healthy elders from those with MCI and AD.37 Better lateral 
orbitofrontal cortex perfusion has been shown to predict better 
neuropsychological response to cholinesterase inhibitors in elders with 
AD.38 Thus, the current study reinforces the early vulnerability and 
predictive power of longitudinal volumetric study of non-hippocampal 
regions in healthy elders who possess an ε4 allele. 
 
Widespread WM atrophy occurred in both carriers and non-
carriers over the course of the five-year follow-up interval. GM atrophy 
appears to show a linear negative correlation with age, whereas age-
related WM microstructure damage and atrophy appear to take place 
in a nonlinear fashion that does not correlate with, and may precede, 
GM atrophy.39,40 Furthermore, WM atrophy in healthy elders has been 
associated with etiological factors that may be independent of AD-
related neuropathology, e.g., hypertension41,42 and depression.43,44 
Alternatively, it is conceivable that WM volumetric measures may be 
less sensitive to AD-related pathology than microstructural changes to 
WM as observed with diffusion tensor imaging.45,46 
 
The current study identified specific hippocampal subfields, 
namely the CA2,3, CA4-DG, presubiculum and subiculum that appear 
to be vulnerable to atrophy in older carriers. Most of the previously 
published longitudinal studies (Table 1) were conducted at 1.5T.7,8,10-14 
The superior signal to noise ratio associated with 3T47,48 is critical for 
delineating hippocampal subfields.49 
 
Most prior studies examined longitudinal changes based on two 
examination periods. By scanning three times over the course of the 
five-year interval, we were in a position to determine if the atrophic 
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changes accelerate over time, as reflected by a significant quadratic 
effect. Our analyses, however, observed no evidence of a quadratic 
change, suggesting that the increases in atrophy were linear in nature. 
 
The current study has its limitations. We were unable to assess 
AD-related pathology directly by examining CSF or PET markers of Aβ 
or tau pathology. It might also have been useful to examine 
inflammatory markers, such as Interleukin-6 (IL6), which can be 
associated with plaque formation.50 Our analysis of hippocampal 
subfields used the automatic FreeSurfer parcellation method, which 
has been criticized by some for accuracy limitations.51 Finally, future 
studies will require replication with a larger and more varied sex and 
ethnicity distribution. 
 
The current study sheds light on the importance of longitudinal 
measurements of total and regional brain volumes for assessing AD-
related neuropathology in genetically atrisk healthy elders. The 
success of future prevention studies hinges on the identification of 
biomarkers that are sensitive to AD-related neuropathology during the 
preclinical stage. Results of our study indicate that volumetric MRI 
may be a candidate biomarker in future prevention studies involving 
APOE ε4 carriers. 
 
Acknowledgements 
 
We thank Piero Antuono, Alissa M. Butts, Kelli L. Douville, Christina M. 
Figueroa, Malgorzata Franczak, Amelia Gander, Evan Gross, Leslie M. 
Guidotti-Breting, Nathan C. Hantke, Kathleen E. Hazlett, Emily Hoida, 
Cassandra Kandah, Christina D. Kay, Melissa A. Lancaster, Monica Matthews, 
Sarah K. Miller, Andria L. Norman, Michael A. Sugarman, and Qi Zhang for 
their assistance. This work was supported by the National Institutes of Health 
Grants R01 AG022304 and M01 RR00058. The content is solely the 
responsibility of the authors and does not necessarily represent the official 
views of the National Institute on Aging or the National Institutes of Health. 
 
Conflict of interest  
 
The authors declare no conflict of interest. 
 
*Corresponding author: Schey Center for Cognitive Neuroimaging, 
Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue/U10, Cleveland, 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Jouranl of Alzheimer’s Disease, Vol 55, No. 4 (2017): pg. 1363-1377. DOI. This article is © IOS Press] and permission has 
been granted for this version to appear in e-Publications@Marquette. IOS Press] does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
14 
 
OH 44195, USA. Telephone: +1 216 444 1025; Fax: +1 216 445 7013; E-
mail address: raos2@ccf.org (S.M. Rao). 
 
References 
 
1Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen 
RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers 
of the Alzheimer’s pathological cascade. The Lancet Neurology 9, 119-
128. 
2Bendlin BB, Carlsson CM, Gleason CE, Johnson SC, Sodhi A, Gallagher CL, 
Puglielli L, Engelman CD, Ries ML, Xu G, Wharton W, Asthana S (2010) 
Midlife predictors of Alzheimer's disease. Maturitas 65, 131-137. 
3Alzheimer's Association (2014) 2014 Alzheimer's disease facts and figures. 
Alzheimer's & Dementia 10, e47-e92. 
4Burggren AC, Zeineh M, Ekstrom AD, Braskie MN, Thompson PM, Small GW, 
Bookheimer SY (2008) Reduced cortical thickness in hippocampal 
subregions among cognitively normal apolipoprotein E e4 carriers. 
Neuroimage 41, 1177-1183. 
5Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, 
Thompson PM, Jack CR, Jr., Weiner MW, Alzheimer's Disease 
Neuroimaging I (2009) MRI of hippocampal volume loss in early 
Alzheimer's disease in relation to ApoE genotype and biomarkers. 
Brain 132, 1067-1077. 
6Ball M, Hachinski V, Fox A, Kirshen A, Fisman M, Blume W, Kral V, Fox H, 
Merskey H (1985) A new definition of Alzheimer's disease: a 
hippocampal dementia. The Lancet 325, 14-16. 
7Jak AJ, Houston WS, Nagel BJ, Corey-Bloom J, Bondi MW (2007) Differential 
crosssectional and longitudinal impact of APOE genotype on 
hippocampal volumes in nondemented older adults. Dement Geriatr 
Cogn Disord 23, 382-389. 
8Moffat S, Szekely C, Zonderman A, Kabani N, Resnick S (2000) Longitudinal 
change in hippocampal volume as a function of apolipoprotein E 
genotype. Neurology 55, 134-136. 
9Rao SM, Bonner-Jackson A, Nielson KA, Seidenberg M, Smith JC, Woodard 
JL, Durgerian S (2015) Genetic risk for Alzheimer's disease alters the 
five-year trajectory of semantic memory activation in cognitively intact 
elders. Neuroimage 111, 136-146. 
10Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, 
Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging I (2011) 
Longitudinal change of biomarkers in cognitive decline. Arch Neurol 
68, 1257-1266. 
11Taylor JL, Scanlon BK, Farrell M, Hernandez B, Adamson MM, Ashford JW, 
Noda A, Murphy GM, Jr., Weiner MW (2014) APOE-epsilon4 and aging 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Jouranl of Alzheimer’s Disease, Vol 55, No. 4 (2017): pg. 1363-1377. DOI. This article is © IOS Press] and permission has 
been granted for this version to appear in e-Publications@Marquette. IOS Press] does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
15 
 
of medial temporal lobe gray matter in healthy adults older than 50 
years. Neurobiol Aging 35, 2479-2485. 
12Nosheny RL, Insel PS, Truran D, Schuff N, Jack CR, Jr., Aisen PS, Shaw LM, 
Trojanowski JQ, Weiner MW, Alzheimer's Disease Neuroimaging I 
(2015) Variables associated with hippocampal atrophy rate in normal 
aging and mild cognitive impairment. Neurobiol Aging 36, 273-282. 
13Crivello F, Lemaitre H, Dufouil C, Grassiot B, Delcroix N, Tzourio-Mazoyer N, 
Tzourio C, Mazoyer B (2010) Effects of ApoE-epsilon4 allele load and 
age on the rates of grey matter and hippocampal volumes loss in a 
longitudinal cohort of 1186 healthy elderly persons. Neuroimage 53, 
1064-1069. 
14Lu PH, Thompson PM, Leow A, Lee GJ, Lee A, Yanovsky I, Parikshak N, Khoo 
T, Wu S, Geschwind D, Bartzokis G (2011) Apolipoprotein E genotype 
is associated with temporal and hippocampal atrophy rates in healthy 
elderly adults: a tensor-based morphometry study. J Alzheimers Dis 
23, 433-442. 
15Raz N, Ghisletta P, Rodrigue KM, Kennedy KM, Lindenberger U (2010) 
Trajectories of brain aging in middle-aged and older adults: regional 
and individual differences. Neuroimage 51, 501-511. 
16Seidenberg M, Guidotti L, Nielson KA, Woodard JL, Durgerian S, Antuono P, 
Zhang Q, Rao SM (2009) Semantic memory activation in individuals at 
risk for developing Alzheimer disease. Neurology 73, 612-620. 
17Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1983) 
Development and validation of a geriatric depression screening scale: 
A preliminary report. Journal of Psychiatric Research 17, 37. 
18Lawton MP, Brody EM (1969) Assessment of Older People: Self-Maintaining 
and Instrumental Activities of Daily Living. The Gerontologist 9, 179-
186. 
19O'Brien DP, Campbell KA, Morken NW, Bair RJ, Heath EM (2001) Automated 
Nucleic Acid Purification for Large Samples. Journal of the Association 
for Laboratory Automation 6, 67-70. 
20Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: A practical 
method for grading the cognitive state of patients for the clinician. 
Journal of Psychiatric Research 12, 189-198. 
21Jurica PJ, Leitten CL, Mattis S (2001) DRS-2 dementia rating scale-2: 
Professional manual, Psychological Assessment Resources, Lutz, FL. 
22Rey A (1958) L'examen clinique en psychologie. 
23Reuter M, Schmansky NJ, Rosas HD, Fischl B (2012) Within-subject 
template estimation for unbiased longitudinal image analysis. 
Neuroimage 61, 1402-1418. 
24Adalbert R, Gilley J, Coleman MP (2007) Abeta, tau and ApoE4 in 
Alzheimer's disease: the axonal connection. Trends Mol Med 13, 135-
142. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Jouranl of Alzheimer’s Disease, Vol 55, No. 4 (2017): pg. 1363-1377. DOI. This article is © IOS Press] and permission has 
been granted for this version to appear in e-Publications@Marquette. IOS Press] does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
16 
 
25Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. 
Cell 148, 1204-1222. 
26Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA 
(2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in 
cognitively normal aging. Ann Neurol 67, 122-131. 
27Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer 
disease: risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118. 
28Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, 
Koeppe RA, Mathis CA, Weiner MW, Jagust WJ, Alzheimer's Disease 
Neuroimaging I (2008) Episodic memory loss is related to 
hippocampal-mediated beta-amyloid deposition in elderly subjects. 
Brain 132, 1310-1323. 
29Du A, Schuff N, Amend D, Laakso M, Hsu Y, Jagust W, Yaffe K, Kramer J, 
Reed B, Norman D (2001) Magnetic resonance imaging of the 
entorhinal cortex and hippocampus in mild cognitive impairment and 
Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry 
71, 441-447. 
30Mueller SG, Schuff N, Raptentsetsang S, Elman J, Weiner MW (2008) 
Selective effect of Apo e4 on CA3 and dentate in normal aging and 
Alzheimer's disease using high resolution MRI at 4 T. Neuroimage 42, 
42-48. 
31Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, 
Mistur R, Tsui WH, de Leon MJ (2010) Subregional hippocampal 
atrophy predicts Alzheimer's dementia in the cognitively normal. 
Neurobiol Aging 31, 1077-1088. 
32Chou YY, Lepore N, de Zubicaray GI, Carmichael OT, Becker JT, Toga AW, 
Thompson PM (2008) Automated ventricular mapping with multi-atlas 
fluid image alignment reveals genetic effects in Alzheimer's disease. 
Neuroimage 40, 615-630. 
33Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, Fogarty 
J, Bartha R, Alzheimer's Disease Neuroimaging I (2008) Ventricular 
enlargement as a possible measure of Alzheimer's disease progression 
validated using the Alzheimer's disease neuroimaging initiative 
database. Brain 131, 2443-2454. 
34Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, 
Peterson R, Weiner MW, Alzheimer's Disease Neuroimaging I (2010) 
Relations between brain tissue loss, CSF biomarkers, and the ApoE 
genetic profile: a longitudinal MRI study. Neurobiol Aging 31, 1340-
1354. 
35Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J (2001) 
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 
heterozygotes: A foundation for using positron emission tomography 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Jouranl of Alzheimer’s Disease, Vol 55, No. 4 (2017): pg. 1363-1377. DOI. This article is © IOS Press] and permission has 
been granted for this version to appear in e-Publications@Marquette. IOS Press] does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
17 
 
to efficiently test treatments to prevent Alzheimer's disease. Proc Natl 
Acad Sci U S A 98, 3334-3339. 
36Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, 
Desgranges B, Baron JC (2005) Using voxel-based morphometry to 
map the structural changes associated with rapid conversion in MCI: a 
longitudinal MRI study. Neuroimage 27, 934-946. 
37McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ, Jr., Holland D, 
Karow DS, Pung CJ, Brewer JB, Dale AM, Alzheimer's Disease 
Neuroimaging I (2009) Alzheimer disease: quantitative structural 
neuroimaging for detection and prediction of clinical and structural 
changes in mild cognitive impairment. Radiology 251, 195-205. 
38Mega MS, Dinov ID, Lee L, O'Connor SM, Masterman DM, Wilen B, Mishkin 
F, Toga AW, Cummings JL (2000) Orbital and Dorsolateral Frontal 
Perfusion Defect Associated With Behavioral Response to 
Cholinesterase Inhibitor Therapy in Alzheimer’s Disease. The Journal of 
Neuropsychiatry and Clinical Neurosciences 12, 209-218. 
39Agosta F, Pievani M, Sala S, Geroldi C, Galluzzi S, Frisoni GB, Filippi M 
(2011) White Matter Damage in Alzheimer Disease and Its 
Relationship to Gray Matter Atrophy. Radiology 258, 853-863. 
40Giorgio A, Santelli L, Tomassini V, Bosnell R, Smith S, De Stefano N, 
Johansen-Berg H (2010) Age-related changes in grey and white matter 
structure throughout adulthood. Neuroimage 51, 943-951. 
41de Leeuw FE, Richard F, de Groot JC, van Duijn CM, Hofman A, Van Gijn J, 
Breteler MM (2004) Interaction between hypertension, apoE, and 
cerebral white matter lesions. Stroke 35, 1057-1060. 
42van Dijk EJ, Breteler MM, Schmidt R, Berger K, Nilsson LG, Oudkerk M, 
Pajak A, Sans S, de Ridder M, Dufouil C, Fuhrer R, Giampaoli S, Launer 
LJ, Hofman A, Consortium C (2004) The association between blood 
pressure, hypertension, and cerebral white matter lesions: 
cardiovascular determinants of dementia study. Hypertension 44, 625-
630. 
43de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MMB 
(2000) Cerebral White Matter Lesions and Depressive Symptoms in 
Elderly Adults. Archives of General Psychiatry 57, 1071-1076. 
44Janssen J, Hulshoff Pol HE, de Leeuw FE, Schnack HG, Lampe IK, Kok RM, 
Kahn RS, Heeren TJ (2007) Hippocampal volume and subcortical white 
matter lesions in late life depression: comparison of early and late 
onset depression. J Neurol Neurosurg Psychiatry 78, 638-640. 
45Persson J, Lind J, Larsson A, Ingvar M, Cruts M, Van Broeckhoven C, 
Adolfsson R, Nilsson LG, Nyberg L (2006) Altered brain white matter 
integrity in healthy carriers of the APOE ε4 allele: A risk for AD? 
Neurology 66, 1029-1033. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Jouranl of Alzheimer’s Disease, Vol 55, No. 4 (2017): pg. 1363-1377. DOI. This article is © IOS Press] and permission has 
been granted for this version to appear in e-Publications@Marquette. IOS Press] does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
18 
 
46Ryan L, Walther K, Bendlin BB, Lue LF, Walker DG, Glisky EL (2011) Age-
related differences in white matter integrity and cognitive function are 
related to APOE status. Neuroimage 54, 1565-1577. 
47Alvarez-Linera J (2008) 3T MRI: advances in brain imaging. Eur J Radiol 67, 
415-426. 
48Willinek WA, Schild HH (2008) Clinical advantages of 3.0 T MRI over 1.5 T. 
Eur J Radiol 65, 2-14. 
49Chow N, Hwang KS, Hurtz S, Green AE, Somme JH, Thompson PM, Elashoff 
DA, Jack CR, Weiner M, Apostolova LG, Alzheimer's Disease 
Neuroimaging I (2015) Comparing 3T and 1.5T MRI for mapping 
hippocampal atrophy in the Alzheimer's Disease Neuroimaging 
Initiative. AJNR Am J Neuroradiol 36, 653-660. 
50Licastro F, Pedrini S, Caputo L, Giorgio A, Davis LJ, Ferri C, Casadei V, 
Grimaldi LME (2000) Increased plasma levels of interleukin-1, 
interleukin-6 and α-1- antichymotrypsin in patients with Alzheimer’s 
disease: peripheral inflammation or signals from the brain? Journal of 
Neuroimmunology 103, 97-102. 
51Wisse LE, Biessels GJ, Geerlings MI (2014) A Critical Appraisal of the 
Hippocampal Subfield Segmentation Package in FreeSurfer. Front 
Aging Neurosci 6, 261. 
 
 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Jouranl of Alzheimer’s Disease, Vol 55, No. 4 (2017): pg. 1363-1377. DOI. This article is © IOS Press] and permission has 
been granted for this version to appear in e-Publications@Marquette. IOS Press] does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
19 
 
Figure Legend: 
 
Figure 1. Longitudinal volumetric change in the left and right total hippocampi (top), 
right CA2,3 and CA4,DG hippocampal subfields (middle), and left and right lateral 
ventricles (bottom) for the APOE e4+ (blue) and e4- (green) groups. The x axis plots 
time in study, indexed in years; y axis indicates brain volume as a percent of 
intracranial volume. Error bars = s.e.m. 
 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Jouranl of Alzheimer’s Disease, Vol 55, No. 4 (2017): pg. 1363-1377. DOI. This article is © IOS Press] and permission has 
been granted for this version to appear in e-Publications@Marquette. IOS Press] does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
20 
 
Table 1: Longitudinal changes in hippocampal and non-hippocampal volume 
in APOE ε4+ and ε4- elders who were cognitively intact and healthy at study 
entry. 
 
Notes: MRI was reported at 1.5T in all studies except Moffat et al. (2000), which was 
unspecified and Rao et al. (2015) reported 3T; ^ = bilateral measurement; 3C=Three 
City Study (France); AD=Alzheimer's disease; ADNI=Alzheimer's Disease 
Neuroimaging Initiative; Aviation=Stanford/VA Aviation Study; BLSA=Baltimore 
Longitudinal Study of Aging; ε4+=presence of an ε4 allele; ε4-=ε4 non-carrier; ε4- 
*=non-ε4 carrier with presence of an ε2 allele; GM=grey matter; HC=hippocampus; 
MT= Manual tracing; MTL=medial temporal lobes; NR= not reported for this group or 
comparison; TC=temporal cortex. 
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Table 2: Baseline characteristics of ε4+ and ε4- groups 
 
Notes: ε4+ = ε4 allele carrier; ε4- = ε4 allele non-carrier; ADL = Activities of Daily 
Living; GDS = Geriatric Depression Scale; MMSE = Mini Mental State Examination; 
DRS = Dementia Rating Scale; RAVLT = Rey Auditory Verbal Learning Test  
*p-values derived from Student's t-test, except for sex (Fisher's exact test) 
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Table 3: Coefficients (±SEM) from linear mixed effects of total hippocampal 
volumes and parcellated hippocampal subfields 
 
Notes: All values in mL; ε4+ = ε4 allele carrier; ε4- = ε4 allele non-carrier; CA = 
cornu ammonis; DG = dentate gyrus; Bolded values are statistically significant after 
controlling for multiple comparisons using false discovery rate 
a Predicted mean intercept (baseline) of each region. Standard errors of coefficients 
are in parentheses. 
b Predicted mean intercept (baseline) of each structure by presence of ε4. Standard 
errors of coefficients are in parentheses. 
c Predicted average yearly rate of change (slope). Standard errors of coefficients are in 
parentheses. 
d Predicted average yearly rate of change (slope) by presence of ε4. Standard errors of 
coefficients are in parentheses. 
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Table 4: Coefficients (±SEM) from linear mixed effects of global cortical grey 
and white matter and ventricular volumes 
 
Notes: all values in mL; ε4+ = ε4 allele carrier; ε4- = ε4 allele non-carrier; GM=gray 
matter; WM=white matter; Bolded values are statistically significant after controlling 
for multiple comparisons using false discovery rate 
a Predicted mean intercept (baseline) of each region. Standard errors of coefficients 
are in parentheses. 
b Predicted mean intercept (baseline) of each structure by presence of ε4. Standard 
errors of coefficients are in parentheses. 
c Predicted average yearly rate of change (slope). Standard errors of coefficients are in 
parentheses. 
d Predicted average yearly rate of change (slope) by presence of ε4. Standard errors of 
coefficients are in parentheses. 
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Table 5: Coefficients (±SEM) from linear mixed effects of Right Hemisphere 
parcellated cortical grey matter regions 
 
Notes: All values in mL; bankssts=banks of the superior temporal sulcus; ε4+ = ε4 
allele carrier; ε4- = ε4 allele non-carrier; OFC=orbitofrontal cortex; Bolded values are 
statistically significant after controlling for multiple comparisons using false discovery 
rate 
a Predicted mean intercept (baseline) of each region. Standard errors of coefficients 
are in parentheses. 
b Predicted mean intercept (baseline) of each structure by presence of ε4. Standard 
errors of coefficients are in parentheses. 
c Predicted average yearly rate of change (slope). Standard errors of coefficients are in 
parentheses. 
d Predicted average yearly rate of change (slope) by presence of ε4. Standard errors of 
coefficients are in parentheses. 
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Table 6: Coefficients (±SEM) from linear mixed effects of Left Hemisphere 
parcellated cortical grey matter regions 
 
Notes: All values in mL; bankssts=banks of the superior temporal sulcus; ε4+ = ε4 
allele carrier; ε4- = ε4 allele non-carrier; OFC=orbitofrontal cortex; Bolded values are 
statistically significant after controlling for multiple comparisons using false discovery 
rate 
a Predicted mean intercept (baseline) of each region. Standard errors of coefficients 
are in parentheses. 
b Predicted mean intercept (baseline) of each structure by presence of ε4. Standard 
errors of coefficients are in parentheses. 
c Predicted average yearly rate of change (slope). Standard errors of coefficients are in 
parentheses. 
d Predicted average yearly rate of change (slope) by presence of ε4. Standard errors of 
coefficients are in parentheses. 
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Table 7: Coefficients (±SEM) from linear mixed effects of Right Hemisphere 
parcellated cortical white matter regions 
 
Notes: All values in mL; bankssts=banks of the superior temporal sulcus; ε4+ = ε4 
allele carrier; ε4- = ε4 allele non-carrier; OFC=orbitofrontal cortex; Bolded values are 
statistically significant after controlling for multiple comparisons using false discovery 
rate 
a Predicted mean intercept (baseline) of each region. Standard errors of coefficients 
are in parentheses. 
b Predicted mean intercept (baseline) of each structure by presence of ε4. Standard 
errors of coefficients are in parentheses. 
c Predicted average yearly rate of change (slope). Standard errors of coefficients are in 
parentheses. 
d Predicted average yearly rate of change (slope) by presence of ε4. Standard errors of 
coefficients are in parentheses. 
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Table 8: Coefficients (±SEM) from linear mixed effects of Left Hemisphere 
parcellated cortical white matter regions 
 
Notes: bankssts= All values in mL; banks of the superior temporal sulcus; ε4+ = ε4 
allele carrier; ε4- = ε4 allele non-carrier; OFC=orbitofrontal cortex; Bolded values are 
statistically significant after controlling for multiple comparisons using false discovery 
rate 
a Predicted mean intercept (baseline) of each region. Standard errors of coefficients 
are in parentheses. 
b Predicted mean intercept (baseline) of each structure by presence of ε4. Standard 
errors of coefficients are in parentheses. 
c Predicted average yearly rate of change (slope). Standard errors of coefficients are in 
parentheses. 
d Predicted average yearly rate of change (slope) by presence of ε4. Standard errors of 
coefficients are in parentheses. 
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Table 9: Coefficients (±SEM) from linear mixed effects of parcellated 
subcortical Grey Matter regions 
 
Notes: All values in mL; ε4+ = ε4 allele carrier; ε4- = ε4 allele non-carrier; Bolded 
values are statistically significant after controlling for multiple comparisons using false 
discovery rate 
a Predicted mean intercept (baseline) of each region. Standard errors of coefficients 
are in parentheses. 
b Predicted mean intercept (baseline) of each structure by presence of ε4. Standard 
errors of coefficients are in parentheses. 
c Predicted average yearly rate of change (slope). Standard errors of coefficients are in 
parentheses. 
d Predicted average yearly rate of change (slope) by presence of ε4. Standard errors of 
coefficients are in parentheses. 
 
 
